Sinovac Biotech (Sinovac Biotech) Total Liabilities : $1,487.8 Mil (As of Jun. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Sinovac Biotech Total Liabilities?

Sinovac Biotech's Total Liabilities for the quarter that ended in Jun. 2023 was $1,487.8 Mil.

Sinovac Biotech's quarterly Total Liabilities increased from Jun. 2022 ($971.93 Mil) to Dec. 2022 ($1,401.91 Mil) and increased from Dec. 2022 ($1,401.91 Mil) to Jun. 2023 ($1,487.75 Mil).

Sinovac Biotech's annual Total Liabilities increased from Dec. 2020 ($781.20 Mil) to Dec. 2021 ($2,872.17 Mil) but then declined from Dec. 2021 ($2,872.17 Mil) to Dec. 2022 ($1,401.91 Mil).

Sinovac Biotech Total Liabilities Historical Data

The historical data trend for Sinovac Biotech's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinovac Biotech Total Liabilities Chart

Sinovac Biotech Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Liabilities

Get a 7-Day Free Trial

77.85

100.10

781.20

2,872.17

1,401.91

Sinovac Biotech Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Total Liabilities	Get a 7-Day Free Trial															3,497.65	2,872.17	971.93	1,401.91	1,487.75

Sinovac Biotech Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Sinovac Biotech's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1091.635	+	(64.029	+	0.23999999999995
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	246.003	+	0)
	=	1,401.9

Total Liabilities	=	Total Assets (A: Dec. 2022 )	-	Total Equity (A: Dec. 2022 )
	=	14114.568	-	12712.661
	=	1,401.9

Sinovac Biotech's Total Liabilities for the quarter that ended in Jun. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1189.629	+	(51.918	+	0.63
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	245.577	+	0)
	=	1,487.8

Total Liabilities	=	Total Assets (Q: Jun. 2023 )	-	Total Equity (Q: Jun. 2023 )
	=	13725.01	-	12237.256
	=	1,487.8

Sinovac Biotech Total Liabilities Related Terms

Thank you for viewing the detailed overview of Sinovac Biotech's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinovac Biotech (Sinovac Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinovac Biotech Ltd (NAS:SVA) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.39, Shangdi Xi Road, Haidan District, Beijing, CHN, 100085

Website

http://www.sinovac.com

Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. The company also provides services for disease control and prevention, collaborating with the Chinese governments at the national, state, and local levels. It sells its vaccines in China, while also exploring growth opportunities in international markets.

Executives

Lily Wang	director, 10 percent owner, officer: Chief Financial Officer	300 MURCHISON DR., MILLBRAE CA 94030
Ifg Investments Services Inc	10 percent owner	PO BOX 822, CHARLESTOWN FEDERATION OF ST KITTS & NEVIS WEST INDIES P8 00000
Yin Weidong	director, 10 percent owner, officer: President and CEO
Terry G Bowering	director, 10 percent owner, officer: President, CEO	10 CEDAR MEADOW DRIVE REGINA A9 S4X 3J6